Cleveland Clinic | Strategic Alliance Partners

Samuel Chao, MD, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, discusses spine stereotactic radiosurgery for the treatment of metastases located on the spine.

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Although precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

One of the central reasons that curing cancer has been so problematic is the dysfunction of TP53, the single most common genetic alteration in cancer.

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

Davendra Sohal, MD, MPH, oncologist and Director of the Clinical Genomics Program at the Cleveland Clinic Taussig Cancer Institute, discusses the feasibility of standardizing genomic profiling and apply precision medicine techniques.

James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.

OncLive today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital's pioneering research and care for cancer patients. Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

With bipartisan support, legislation aimed at reducing the high copays for self-injectable and oral cancer drugs was introduced in the House and Senate.

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses the results of the phase III POEMS study, which was presented at the 2014 ASCO Annual Meeting.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.